Abstract #0850
Metabolic characterization of triple negative breast cancer
Guro Fannelb Giskedegrd 1,2 , Maria Dung Cao 1,2 , Santosh Lamichhane 3 , Beathe Sitter 4 , Anna Bofin 5 , Steinar Lundgren 2 , Hans Fjsne 2 , and Tone Frost Bathen 1
1
Dept. of Circulation and Medical Imaging,
NTNU, Trondheim, Norway,
2
St.
Olavs University Hospital, Trondheim, Norway,
3
Department
of Food Science, Aarhus University, Denmark,
4
Sr-Trndelag
University College, Norway,
5
NTNU,
Trondheim, Norway
Triple negative breast cancer (TNBC), characterized by
estrogen receptor (ER), progesterone receptor (PgR) and
HER2 negativity, represents 15-20% of all breast cancer
cases. TNBC is associated with more aggressive and
higher grade tumors and poor prognosis. Current
treatment options for TNCB are few and the responses are
often insufficient. Novel molecular targets for the
treatment of TNBC are needed to improve treatment care
and survival of this breast cancer subgroup. The purpose
of this study was to characterize metabolic differences
between TNBC as compared to triple positive breast
cancer and to identify potential molecular markers of
TNBC tumors for targeted treatment.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
